XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Statements of Cash Flows - USD ($)
 9 Months Ended
Mar. 31, 2022
Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (6,326,866) $ (6,749,317)
Adjustments to reconcile net loss to net cash used in operating activities    
Preferred shares issued as compensation 105,658 175,200
Preferred shares issued pursuant to license agreement 935,088 0
Common shares issued as compensation and for services 129,018 137,288
Warrants granted to Scientific Advisory Board 3,781 4,951
Depreciation 529,167 522,172
Amortization of loan origination fees 0 18,013
Amortization 6,202 6,202
Loss on disposal of property and equipment 0 2,026
Write-off of deferred financing costs 0 12,190
Changes in operating assets and liabilities:    
Prepaid expenses 204,118 180,988
Other assets (45,702) 10,158
Accounts payable (77,029) (282,492)
Accounts payable - related party 42,048 21,495
Accrued expenses 967 (45,012)
NET CASH USED IN OPERATING ACTIVITIES (4,493,550) (5,986,138)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property and equipment (248,986) (154,122)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Net proceeds from issuance of common stock and warrants 0 16,563,697
Payment of note payable - related party 0 (1,100,000)
Deferred financing costs (37,408) 0
Payment of loan payable (164,599) (132,513)
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES (202,007) 15,331,184
NET CHANGE IN CASH AND CASH EQUIVALENTS (4,944,543) 9,190,924
Cash and cash equivalents at beginning of period 20,516,677 13,708,594
Cash and cash equivalents at end of period 15,572,134 22,899,518
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:    
Interest paid 3,488 3,171
Non-Cash Financing and Investing Activities:    
Directors and Officers Insurance financed through loan $ 234,198 $ 235,476